The Japanese pharma market is set for strong growth in 2019, with expected growth of solid dose formulations improving by more than 10% with generic drug classes highlighted as offering strong growth prospects. Japan’s ageing population combined with the government’s initiative to reduce health expenditure is expected to result in the volume share of generic drugs reaching 80% or more by 2020. There is currently a strong focus on the generic drugs sector with the nation's government going as far as to identify the growth of its generic drugs market as "imperative to Japan's long-term economic health.
In terms of its own domestic manufacturing, Japan’s outstanding reputation for quality remains undiminished. For finished dose manufacturing, Japan (7.95) scored jointly top alongside the USA (8.01) and Germany (8.07) in the last two years of the CPhI Annual Report pharma index*.
* source: CPhI 2018 Annual Industry Report